Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Industry

Tapestry VC Closes $80M Fund III Backed by British Business Bank to Target Repeat Founders

Sreepriya Prasannan
Sreepriya Prasannan
Speed:
Tapestry VC Closes $80M Fund III Backed by British Business Bank to Target Repeat Founders

Irish-founded venture capital firm Tapestry VC has officially closed its third investment vehicle, Fund III, raising $80 million (€70 million) to back early-stage founders across Europe and North America. The fund is nearly triple the size of Tapestry's previous vehicle, highlighting the firm's growth and strong reputation in the global technology ecosystem.

Founded in 2018 by Irish venture capitalists Patrick Murphy and David Kelly, Tapestry VC has developed a highly targeted investment philosophy: focusing almost exclusively on repeat founders at the pre-seed and seed stages across software, AI, fintech, and deep tech.

Triple the Capital to Fuel Larger Seed Checks

With the closing of Fund III, Tapestry will significantly scale up its participation in competitive seed rounds. Typical check sizes will increase to between $1 million and $3 million, up from the $500,000 to $1 million range in previous funds. The firm plans to build a concentrated portfolio of approximately 30 companies, offering hands-on assistance with hiring, international expansion, and follow-on fundraising.

The fund's investor base represents a high-profile mix of institutional investors and tech executives. The British Business Bank acts as the fund's co-anchor with a $40 million commitment, alongside returning institutional LPs including Railpen and Molten Ventures. Additionally, Sarah Friar, the CFO of OpenAI and a long-time supporter of Tapestry, participates as an investor and advisor.

A Track Record of Early AI and Tech Wins

Tapestry's success is anchored by early-stage bets on some of Europe's most prominent technology success stories. Its portfolio includes:

  • Manna: The pioneering Irish drone delivery startup founded by Bobby Healy.
  • Nothing: The consumer electronics startup led by OnePlus co-founder Carl Pei.
  • Fin: The AI-driven customer service platform (originally part of Intercom) which was acquired by Salesforce in a landmark deal valued at approximately $3.6 billion.

"We believe that serial founders-those who have already built, scaled, or exited companies-have a unique advantage in navigating the early-stage landscape," remarked David Kelly. "Fund III gives us the capital density to lead their rounds and help them build global winners."

Establishing a Dual London-San Francisco Axis

To support its growing European portfolio, Tapestry is establishing a new flagship office in London. Co-founder Patrick Murphy is relocating from San Francisco to head the London operations, working closely with European tech hubs while David Kelly continues to lead the firm's presence in San Francisco.

This dual presence allows Tapestry to act as a bridge for European startups looking to expand into the US market, and vice versa. "The lines between Silicon Valley, London, and continental Europe are blurring," added Patrick Murphy. "Our goal is to be the first-choice partner for founders who think globally from day one."

Tapestry VC Fund III: Backing High-Growth Startups

Tapestry VC's successful closing of its $80 million Fund III, supported by the British Business Bank, marks a significant boost for early-stage technology investments in the UK and Ireland. The fund will focus on backing repeat founders and high-potential startups in areas like artificial intelligence, deep tech, and enterprise software. Tapestry VC's investment philosophy is centered on providing active, hands-on support during the seed and Series A phases, helping founders build global businesses.

The British Business Bank's participation, through its Enterprise Capital Funds program, underscores the state's focus on unlocking venture capital for high-growth tech firms. The new fund will target investments across Europe, with a particular focus on the London and Dublin tech hubs.

Frequently Asked Questions

What is Tapestry VC's investment focus for Fund III?

Fund III will focus on seed and early-stage investments in technology startups, with a preference for backing repeat founders in software and deep-tech sectors.

How is the British Business Bank involved in the fund?

The British Business Bank is a major cornerstone investor in Fund III, providing capital through its Enterprise Capital Funds program to stimulate early-stage VC investments.

What regions will the new Tapestry fund target?

The fund will invest across the European technology ecosystem, prioritizing active tech clusters in the UK, Ireland, and the Nordics.

Frequently Asked Questions

What does 'Fund III' mean for Tapestry VC?

Fund III represents Tapestry VC's third investment fund, raising $80 million in capital to back early-stage technology startups.

What is a repeat founder and why does Tapestry prioritize them?

A repeat founder is an entrepreneur who has previously started and run a company. Investors prioritize them because they have experience navigating startup growth and challenges.

How does the British Business Bank support venture capital?

Through its Enterprise Capital Funds program, the British Business Bank invests in early-stage VC funds, increasing the availability of venture funding for small businesses.

Frequently Asked Questions

What does 'Fund III' mean for Tapestry VC?

Fund III represents Tapestry VC's third investment fund, raising $80 million in capital to back early-stage technology startups.

What is a repeat founder and why does Tapestry prioritize them?

A repeat founder is an entrepreneur who has previously started and run a company. Investors prioritize them because they have experience navigating startup growth and challenges.

How does the British Business Bank support venture capital?

Through its Enterprise Capital Funds program, the British Business Bank invests in early-stage VC funds, increasing the availability of venture funding for small businesses.

Reviewed for editorial accuracy by Sreepriya Prasannan, Founder & Editor MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany
Our standards
Drugs in this article: current clinical trials
Most-trialled drugs in our registers
Browse all trial registers →

Get the Friday brief

One email every Friday: the week's Irish pharma news, new EMA and FDA approvals, EU and US medicine shortages and how many trials are recruiting in Ireland, built from public registers.

Free. Unsubscribe from any email with one click. See our privacy policy.

About the Author
Sreepriya Prasannan

Sreepriya Prasannan

Writer at Priya Life Science · Industry

Sreepriya Prasannan is the Founder and Editor of Priya Life Science, Ireland's independent pharma, biotech and MedTech platform. She holds an MSc in Digital Transformation (Life Science) from Griffith College Dublin, with a background in QA, GMP and production operations. Shortlisted for STEM Graduate of the Year at the Business Post Women in STEM Awards 2026 and a Top 14 finalist in the HSE Spark Ignite 2026 innovation programme, she writes on regulatory trends, GMP compliance and careers across the Irish and European life sciences.

Discussion
No comments yet. Be the first to share your thoughts!
Leave a Comment